IVIg vs placebo or no treatment
Overall survival (risk of death) ‐ children with myocarditis, 6‐month · children with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ children with myocarditis, 6‐month compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Intravenous immunoglobulin for presumed viral myocarditis in children and adults 2020 · Cochrane Headline outcomes onlyRR 0.48 [0.2, 1.15]1 study · 86 participantsVery low